Literature DB >> 25537439

Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.

Laura Ferrari1, Simona Sada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25537439     DOI： 10.1007/s11739-014-1173-5

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  5 in total

1.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

4.  Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase.

Authors:  Christine Maric; Wei Zheng; Thomas Walther
Journal:  Nephron Physiol       Date:  2006-03-25

5.  Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

Authors:  Milton Packer; Robert M Califf; Marvin A Konstam; Henry Krum; John J McMurray; Jean-Lucien Rouleau; Karl Swedberg
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690
  5 in total
  4 in total

1.  The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

Authors:  Giuseppe Mulè; Alessandra Sorce; Emilio Nardi; Giulio Geraci; Santina Cottone
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 3.397

Review 2.  [Cardio-renal axis : Relationship of heart failure and renal insufficiency as comorbidities].

Authors:  M Zeisberg; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

Review 3.  Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.

Authors:  Cristina Panico; Gianluigi Condorelli
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.

Authors:  Qianlan Xi; Zijun Chen; Tingming Li; Liya Wang
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.